Onxeo Strengthens Its Executive Management Team

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)-- Regulatory News :

Onxeo SA (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, Nasdaq OMX Copenhagen
- ONXEO), an innovative company specialised in orphan oncology treatments, has
strengthened its management team with three new senior appointments.

•Elisabeth Carstensen appointed Director of Alliance Management
•Graham Dixon appointed CSO/Head of R&D
•Audrey Legentil-Duméry appointed Director of Human Resources
Judith Greciet, CEO of Onxeo, declared: “Significantly strengthening our
executive management team goes hand in hand with the implementation of our
strategic growth plan. Partnerships, R&D and HR are all crucial to accelerating
our development and succeeding in our ambition to become a global leader in
orphan oncology. Stemming from varied cultural backgrounds and perfectly
accustomed to operating in the biotech universe, I am convinced that Elisabeth,
Graham and Audrey will greatly contribute to Onxeo’s future development.”

Elisabeth Carstensen, Director of Alliance Management

Elisabeth will head a newly created department responsible for coordinating and
optimising Onxeo’s relationships with commercial as well as international
development partners, significant sources of revenues for the company. Elisabeth
Carstensen holds a PhD in organic chemistry and a Master’s degree in chemical
engineering from the Technical University of Denmark. Initially responsible for
the pharmaceutical development of Belinostat, Elisabeth was lately Director of
Business Development and Partnership Management with Topotarget. Elisabeth has
also been appointed Director of Onxeo’s Danish operation, ensuring the link
between the group’s two entities.

Graham Dixon, CSO/ Head R&D

Heading the R&D department, Graham Dixon, will be responsible with his teams for
leading project development up through commercialisation, strengthening
portfolio projects and fostering collaboration with academic experts on
promising programmes.

Graham Dixon has a twenty year track record in research and development in
pharmaceutical industry, particularly oncology, having held senior management
positions within big pharma and biotech. For nearly ten years, Graham worked as
Director of R&D with the European biotech Galapagos, accompanying its growth and
international development.

Graham Dixon holds a PhD in Biochemistry from the University of Swansea, Wales
and an honors degree in Biology from the Universtiy of Bradford. He has numerous
patents and scientific publications.

Audrey Legentil-Duméry, Director of Human Resources

A human resources department, headed by Audrey Legentil-Duméry, has been created
to support Onxeo’s rapid growth and will support international development and
talent management, notably in the integration of the French and Danish teams.
Previously, Audrey Legentil-Duméry worked as a Senior HR consultant with a Paris
-based agency, managing HR on behalf of diverse companies, notably accompanying
SME’s through periods of growth and transition. Audrey successfully conducted
several missions in the pharma and biotech sectors. Audrey holds a Master in
Management and Intercultural Communication from CELSA (Sorbonne, Paris).

Pierre Attali, MD, MSc, General Deputy Manager in charge of Strategy and Medical
Affairs, is leaving the company to focus on other projects and may continue to
collaborate with Onxeo as an advisor.

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives to “make the difference”. The Onxeo teams are determined to develop
innovative medicines to provide patients with hope and significantly improve
their lives.

Key products at advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis: Positive
preliminary top-line results
Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma

For more information, visit the website www.onxeo.com

Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference
Document filed with the AMF on April 7, 2014, which is available on the AMF
website (http://www.amf-france.org) or on the company’s website (www.onxeo.com)
Contacts
Onxeo
Judith Greciet, CEO
j.greciet@onxeo.com
or
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Alize RP
Caroline Carmagnol / Sophie Colin, +33 6 64 18 99 59 / +33 1 44 54 36 62
onxeo@alizerp.com